Expanding what’s possible in precision cancer treatment

Cancer is one of the most devastating and pervasive diseases of our time. Tavros aims to understand how cancer evolves so we can better identify unique druggable vulnerabilities for high-unmet need patient populations. Our goal is to target the right new drugs to the right patients to improve clinical trial success rates, patient outcomes and quality of life.

By harnessing the power of synthetic lethality, one of the most promising areas of genetically targeted cancer treatment, we can find and target gene pairs with vulnerabilities to inhibition and target them with precision medicine.


By applying our deep expertise in cancer biology with pioneering high-throughput functional genomic approaches, Tavros has built a next-generation, bi-directional synthetic lethality platform that can precisely and directly identify the paired genetic interactions – with unprecedented speed and scalability – that form the basis for breakthrough targets and first-in-class cancer drugs, new scientific targets and biomarkers.

Cutting-edge functional genomics and computational analysis accelerate the discovery of de-risked, druggable targets with the ultimate goal of improving patient outcomes, minimizing toxicity and quickening development in defined patient subsets.


Our proprietary platform is also an internal discovery engine building a highly innovative pipeline of small-molecule precision therapies for category-defining, groundbreaking treatments.